


# WORLD MALARIA REPORT 2017



World Health  
Organization



# WORLD MALARIA REPORT 2017



**World Health  
Organization**

World malaria report 2017

ISBN 978-92-4-156552-3

© **World Health Organization 2017**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** World malaria report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Map production: WHO Global Malaria Programme and WHO Public Health Information and Geographic Systems.

Layout: [designisgood.info](http://designisgood.info)

Please consult the WHO Global Malaria Programme website for the most up-to-date version of all documents ([www.who.int/malaria](http://www.who.int/malaria))

Printed in Luxembourg

# Contents

|  |           |
|--|-----------|
| Foreword   | iv        |
| Acknowledgements   | vii       |
| Abbreviations  | xi        |
| Key points   | xii       |
| <b>1. Global malaria targets and milestones</b>  | <b>2</b>  |
| <b>2. Investments in malaria programmes and research</b>   | <b>4</b>  |
| 2.1. Total expenditure for malaria control and elimination   | 4         |
| 2.2 Total expenditure for malaria research and development   | 6         |
| 2.3 Deliveries of insecticide-treated mosquito nets  | 7         |
| 2.4 Deliveries of rapid diagnostic tests   | 9         |
| 2.5 Deliveries of artemisinin-based combination therapies  | 10        |
| <b>3. Preventing malaria</b>   | <b>12</b> |
| 3.1 Population at risk sleeping under an insecticide-treated mosquito net  | 12        |
| 3.2 Population at risk protected by indoor residual spraying   | 15        |
| 3.3 Population at risk sleeping under an insecticide-treated mosquito net or protected by indoor residual spraying | 17        |
| 3.4 Pregnant women receiving three or more doses of intermittent preventive treatment                              | 18        |
| 3.5 Seasonal malaria chemoprevention   | 19        |
| <b>4. Diagnostic testing and treatment</b>   | <b>22</b> |
| 4.1 Children aged under 5 years with fever for whom advice or treatment was sought from a trained provider         | 22        |
| 4.2 Suspected malaria cases receiving a parasitological test   | 24        |
| 4.3 Malaria cases receiving first-line antimalarial treatment according to national policy                         | 26        |
| 4.4 Artemisinin-based combination therapy treatments among all malaria treatments                                  | 27        |
| 4.5 Integrated community case management   | 28        |
| <b>5. Malaria surveillance systems</b>   | <b>30</b> |
| 5.1 Health facility reports received at national level   | 30        |
| 5.2 Malaria cases detected by surveillance systems   | 30        |
| <b>6. Regional and global trends in malaria cases and deaths</b>   | <b>32</b> |
| 6.1 Estimated number of malaria cases by WHO region, 2000–2015   | 33        |
| 6.2 Malaria case incidence rate  | 38        |
| 6.3 Estimated number of malaria deaths and mortality rate by WHO region, 2010–2016                                 | 41        |
| <b>7. Malaria elimination and prevention of re-establishment</b>   | <b>44</b> |
| 7.1 E-2020 initiative  | 46        |
| 7.2 WHO support structures for malaria eliminating countries   | 47        |
| <b>8. Responding to threats to the fight against malaria</b>   | <b>48</b> |
| 8.1 Funding for malaria  | 48        |
| 8.2 Malaria in complex situations  | 50        |
| 8.3 False-negative diagnosis due to parasite deletion of histidine-rich proteins                                   | 54        |
| 8.4 Parasite resistance – antimalarial drug efficacy and response  | 54        |
| 8.5 Insecticide resistance   | 58        |
| <b>9. Conclusion</b>   | <b>60</b> |
| References   | 62        |
| Annexes  | 65        |

# Foreword



**Dr Tedros Adhanom Ghebreyesus**

Director-General  
World Health Organization

For many years, the global response to malaria was considered one of the world's great public health achievements. WHO reported time and again on the massive roll-out of effective disease-cutting tools, and on impressive reductions in cases and deaths.

Last December, we noted a troubling shift in the trajectory of this disease. The data showed that less than half of countries with ongoing transmission were on track to reach critical targets for reductions in the death and disease caused by malaria. Progress appeared to have stalled.

The *World malaria report 2017* shows that this worrying trend continues. Although there are some bright spots in the data, the overall decline in the global malaria burden has unquestionably leveled off. And, in some countries and regions, we are beginning to see reversals in the gains achieved.

## Global disease burden and trends

In 2016, 91 countries reported a total of 216 million cases of malaria, an increase of 5 million cases over the previous year. The global tally of malaria deaths reached 445 000 deaths, about the same number reported in 2015.

Although malaria case incidence has fallen globally since 2010, the rate of decline has stalled and even reversed in some regions since 2014. Mortality rates have followed a similar pattern.

The WHO African Region continues to account for about 90% of malaria cases and deaths worldwide. Fifteen countries – all but one in sub-Saharan Africa – carry 80% of the global malaria burden. Clearly, if we are to get the global malaria response back on track, supporting the most heavily affected countries in this region must be our primary focus.

## Extending health care to all

As WHO Director-General, achieving universal health coverage is my top priority. This is based on the moral conviction that all people should be guaranteed access to the health services they need, when and where they need them, regardless of where they live or their financial status.

To this end, how have countries fared in delivering services that prevent, diagnose and treat malaria for all in need? While we have made important headway, the pace of progress must be greatly accelerated if we are to reach our global malaria targets for 2020 and beyond.

In 2016, just over half (54%) of people at risk of malaria in sub-Saharan Africa were sleeping under an insecticide-treated mosquito net – the primary prevention method. This level of coverage represents a considerable increase since 2010 but is far from the goal of universal access.

Spraying the inside walls of homes with insecticides (indoor residual spraying, IRS) is another important prevention measure. The report documents a precipitous drop in IRS coverage in the WHO African Region since 2010, as well as declines in all other WHO regions over this same period.

Prompt diagnosis and treatment is the most effective means of preventing a mild case of malaria from developing into severe disease and death. In the WHO African Region, most people who seek treatment for malaria in the public health system receive an accurate diagnosis and effective medicines.

However, access to the public health system remains far too low. National-level surveys in the WHO African Region show that only about one third (34%) of children with a fever are taken to a medical provider in this sector.

## **Inadequate investment**

A minimum investment of US\$ 6.5 billion will be required annually by 2020 in order to meet the 2030 targets of the WHO global malaria strategy. The US\$ 2.7 billion invested in 2016 represents less than half of that amount. Of particular concern is that, since 2014, investments in malaria control have, on average, declined in many high-burden countries.

## **Malaria response at a cross-roads**

The choice before us is clear. If we continue with a “business as usual” approach – employing the same level of resources and the same interventions – we will face near-certain increases in malaria cases and deaths.

It is our hope that countries and the global health community choose another approach, resulting in a boost in funding for malaria programmes, expanded access to effective interventions and greater investment in the research and development of new tools.

As I have said before, countries must be in the driver’s seat; they alone are ultimately responsible for the health of their citizens. Universal health coverage is indeed a political choice – one that takes courage, compassion and long-term vision.

After spending many years fighting the scourge of malaria in Ethiopia, I know that we are up against a tough adversary. But I am also convinced that this is a winnable battle. With robust financial resources and political leadership, we can – and will – swing the pendulum back towards a malaria-free world.







预览已结束，完整报告链接和二

<https://www.yunbaogao.cn/report/index/report?re>